0001209191-23-010544.txt : 20230217
0001209191-23-010544.hdr.sgml : 20230217
20230217161243
ACCESSION NUMBER: 0001209191-23-010544
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230215
FILED AS OF DATE: 20230217
DATE AS OF CHANGE: 20230217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Martin Daniel C.
CENTRAL INDEX KEY: 0001752827
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 23642647
MAIL ADDRESS:
STREET 1: C/O DECIPHERA PHARMACEUTICALS, INC.
STREET 2: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001654151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200299725
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-209-6400
MAIL ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20150928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-15
0
0001654151
Deciphera Pharmaceuticals, Inc.
DCPH
0001752827
Martin Daniel C.
C/O DECIPHERA PHARMACEUTICALS, INC.
200 SMITH STREET
WALTHAM
MA
02451
0
1
0
0
Chief Commercial Officer
Common Stock
2023-02-15
4
A
0
11151
0.00
A
59540
D
Common Stock
2023-02-16
4
S
0
1159
15.099
D
58381
D
Stock Option (Right to Buy)
15.48
2023-02-15
4
A
0
44600
0.00
A
2033-02-14
Common Stock
44600
44600
D
The reporting person was awarded 11,151 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2024, February 15, 2025 and February 15, 2026.
This sale was to cover tax liabilities in the vesting of restricted stock.
This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2023.
/s/ Jeffrey M. Held, Attorney-in-Fact
2023-02-17